.Attributes Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a mean follow-up of 11 months, patients with metastatic gastrointestinal lumps that obtained biomarker-matched treatments based on flowing lump DNA profiling revealed a more significant medical benefit than those receiving unparalleled therapy.